Investor Presentation

4th November, 2026 To, To, The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, ‘Exchange Plaza’, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 533573 NSE Symbol: APLLTD Dear Sir/Madam, Sub: Investor Presentation on Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026 Please find enclosed herewith the Investor Presentation on the Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026. We request you to kindly take the same on record. Thanking you, Yours faithfully, For Alembic Pharmaceuticals Limited Chirag K. Shukla Company Secretary Encl.: A/a. ALEMBIC PHARMACEUTICALS LIMITED REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. ● TEL: (0265) 2280550, 2280880 ● FAX: (0265) 2281229 Website : www.alembicpharmaceuticals.com ● E-mail : alembic@alembic.co.in ● CIN : L24230GJ2010PLC061123 Alembic Pharmaceuticals Limited Investor Presentation Q2 FY27 Safe Harbour Statement The materials and information presented herein may include forward looking statements , which reflect current expectations, projections, and assumptions. These statements are inherently subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those anticipated. Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product related, forward-looking statements. Product risks and uncertainties include but are not limited to technological advances and patents attained by competitors, challenges inherent in new product development including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trend towards managed care and healthcare cost containment, and governmental laws and regulations affecting domestic and foreign operations. Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to the inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance. Alembic Pharmaceuticals Ltd. Investor Presentation Q2 FY27 2 Q2FY27 financial performance REVENUE EBITDA MARGIN PAT GROSS MARGIN R&D SPEND ₹26.03 bn +520 bps ₹3.35 bn 73.7% 8% +36% YoY ₹5.78 bn; +78% YoY +81% YoY +70 bps YoY of revenue Core margin Execution expansion momentum across markets Revenue growth All businesses registered double digit growth margin expansion in base portfolio; - India chronic portfolio gaining momentum funding R&D to build specialty portfolio and - US Branded traction building the US Branded platform 14% 77% 39% 12% India US API Ex-US Alembic Pharmaceuticals Ltd. Investor Presentation Q2 FY27 3 Robust growth trajectory across businesses INR Bn Business Q2 FY26 Q2 FY27 Y-o-Y Q1 FY27 Q-o-Q H1 FY26 H1 FY27 Y-o-Y Formulations India Branded Business 6.39 7.25 14% 6.42 13% 12.38 13.67 10% US 5.66 10.03 77% 7.78 29% 10.89 17.81 64% Ex-US 3.92 4.40 12% 3.83 15% 7.19 8.23 14% API 3.14 4.36 39% 3.46 26% 5.75 7.82 36% Total Revenue 19.1 26.03 36% 21.50 21% 36.21 47.53 31% Q2 FY27 US Formulation 16% India Branded Business Ex-US Formulation Alembic Pharmaceuticals Ltd. Investor Presentation Q2 FY27 4 India Branded Business (1/2) Revenue Q2 FY27 Growth: 14% INR Bn Revenue Trend CAGR: 6% INR Bn 7.25 6.39 24.58 23.39 1.69 22.00 20.63 1.38 19.26 Animal Health 1.77 1.78 Acute 3.79 3.23 Specialty Q2FY26 Q2FY27 FY22 FY23 FY24 FY25 FY26 Sales Mix Q2 FY27  11% y-y growth in Human Health portfolio Anti Infective ― growth in Specialty portfolio ~17%; outperforming market Cough & Cold ― Human Health growth gap vs market narrowing 8% Gynecology  Animal Health sustained growth momentum 23% Cardiology  Alembic is ranked 20th in the Indian Pharmaceutical Market (IPM); 1.1% Gastrology market share of the Indian pharma space* Anti Diabetic  Six flagship brands have surpassed INR 1 billion in sales 9% 13% Others  Sales operations include 5,800+ Medical Representatives Animal health Alembic Pharmaceuticals Ltd. Investor Presentation Q2 FY27 *Source: IQVIA MAT Sep-26 5 India Branded business (2/2) Top Brands with Rank and Market Share Driving overall Prescription business BRANDS Rank MS% BRANDS Rank MS% 133.2 137.6 Q2 Q2 Q2 Q2 FY 27* FY 27* FY 27* FY 27* 0.249 0.244 AZITHRAL 1 31.0 FREEGO 2 9.4 ALTHROCIN 1 88.2 WIKORYL 3 9.3 CRINA-NCR 1 32.9 ISOFIT 3 5.8 ROXID 1 95.4 ULGEL 3 8.0 DELTONE 1 50.6 BLADMIR 3 8.8 GERIJOINT 1 35.0 VELDROP 3 5.0 ELATA 1 56.4 OVIGYN DH 3 10.3 CETANIL 2 6.9 BROZEET-LS 4 5.1 GESTOFIT SR 2 19.4 ETRIK 4 5.1 LACTONIC 2 20.6 CLOFF 4 12.1 ESTROPLUS 2 36.5 BILAMBIC-M 4 5.5 *Prescriptions (in Mn) *Prescribers (in Mn) ISOFIT SR 2 14.5 TELLZY 5 3.8 MAT Sep-25 MAT Sep-26 Sep-25 Sep-26 TRAVISIGHT 2 19.2 HARMONI 5 5.3 UNIGOLIX 2 14.5  Alembic ranks 17th by prescription volume, with a total of 137.6 million prescriptions (MAT Sep 2026). * Above market growth is based on respective molecule group. Source: IQVIA Sep-26 Alembic Pharmaceuticals Ltd. Investor Presentation Q2 FY27 6 Animal Health Business Revenue Q2 FY27 Growth: 23% INR Bn Revenue Trend CAGR: 22% INR Bn 5.19 4.31 3.55 2.81 1.69 2.32 1.38 Q2FY26 Q2FY27 FY22 FY23 FY24 FY25 FY26 Sales Mix Q2 FY27  A well-established portfolio of strong brands continues to drive growth- operates in the Livestock, Poultry, and Companion Animal segments. Feed Supplement 33%  Market leader in Haematinicsand Antibiotics with brands such as Antibiotic Sharkoferrol, Moxel, Xceftand Mceft.` Tonic Annual SalesValue INR Bn Supportive 11% Above 0.3 0.2 –0.3 0.1 –0.2 38% Therapy 11% Antiparasitic No. of Brands 6 3 5 Alembic Pharmaceuticals Ltd. Investor Presentation Q2 FY27 7 US Business Revenue Q2 FY27 Growth: 77% INR Bn Revenue Trend CAGR: 7% INR Bn 22.06 19.57 16.66 17.3 15.72 10.03 5.66 Q2FY26 Q2FY27 FY22 FY23 FY24 FY25 FY26 Approved ANDAs  10 products launched in H1 FY27 with a total number of 188 products commercialized as on date. Total 245* 22 2  Strong and well-diversified pipeline, with a sharper focus on ramping up * Includes 20 Tentative Approvals 23 our presence in complex platforms and specialty segments Q2FY27 : 5 ANDA Filings,1 Approvals.  Alembic Therapeutics-Portfolio established; commercial traction is Cumulative : 283 ANDA Filings, 245 building approvals and 188 Products Launched so far. Oral Solids Derma Ophthalmic Injectable Inhalation Alembic Pharmaceuticals Ltd. Investor Presentation Q2 FY27 8 Ex-US Business Revenue Q2 FY27 Revenue Trend INR Bn Growth: 12% INR Bn CAGR: 18% 14.94 4.40 3.92 12.43 10.52 Q2FY26 Q2FY27 8.52 7.75  Growth led by Europe,supported by Canada and Emerging market including Chile  Leveraging US product portfolio and regulatory approved facilities enabling expansion across key geographies  Subsidiaries incorporated in Germany, Philippines and Thailand for further expansion FY22 FY23 FY24 FY25 FY26 Alembic Pharmaceuticals Ltd. Investor Presentation Q2 FY27 9 API Business Revenue Q2 FY27 Growth: 39% Revenue Trend INR Bn CAGR: 6% INR Bn 12.46 11.87 4.36 11.66 11.33 3.14 9.39 Q2FY26 Q2FY27  Volume led growth underpinned by healthy customer demand.  1 US DMF filed in Q2 FY27. 153 Cumulative DMF filings with the US FDA  Continued focus on cost efficiency to remain competitive FY22 FY23 FY24 FY25 FY26 Alembic Pharmaceuticals Ltd. Investor Presentation Q2 FY27 10 Dosage Form-wise ANDA Approval and Launch – H1 FY27 Continued investment in building product pipelines INR Bn *Approval (11) 15.8% 7 Launched (10) 6 12.8% 5 9.6% 4 7.8% R&D Spend 7.6% 3 8.4 2 2 2 2 7.2 7.1 1 1 4.8 5.2 OSD OSD-Onco Injectables Derma FY22 FY23 FY24 FY25 FY26 *Appr [Showing first 8,000 characters — download PDF for full document]